National psoriasis foundation medical board consensus statement on biologic therapies

2005 ◽  
Vol 52 (3) ◽  
pp. P191
2019 ◽  
Vol 5 (1) ◽  
pp. 28-31
Author(s):  
Amy Blake ◽  
Clinton Enos ◽  
April W. Armstrong ◽  
Amit Garg ◽  
Alice Gottlieb ◽  
...  

Background: There is limited literature on the occurrence and management of psoriasis involving the ear. Objective: To better understand psoriasis of the ear and current approaches for management. Methods: The Medical Board of the National Psoriasis Foundation was surveyed on the frequency and presentation of psoriasis of the ear, the types of examinations performed, and the rationale for choice of treatment. Results: In this survey, the observed frequency of ear psoriasis was wide (10%-70%). The scalp was the most common concurrent site of extra-auricular psoriasis. Inspection of the ear was commonly reported; however, 75% of respondents report not inspecting the canal. Topical corticosteroids were the most commonly used treatment. Systemic and biologic therapies are infrequently used. Limitations: This study is limited by the sample size of respondents. Not every question of the survey was answered by all those surveyed. Conclusions: Results from our survey suggest that the evaluation of psoriasis of the ear is often not complete. Inspection of the ear, including the canal, is recommended, especially if the scalp is involved. Routine inspection of the ear is recommended both to evaluate treatment response and for potential adverse side effects. In the setting of persistent ear disease, collaboration between dermatologists and otolaryngologists is encouraged.


2018 ◽  
Vol 3 (2) ◽  
pp. 65-70 ◽  
Author(s):  
Monique Kamaria ◽  
Wilson Liao ◽  
J. Y. Koo

The biologic agents vary considerably in terms of their long-term duration of effect. Using the definitions provided by the National Psoriasis Foundation Medical Board, the objective of this review was to compare all biologic agents with respect to time to relapse and potential for rebound. Overall, alefacept had the longest off-treatment benefit (29.9 weeks in Psoriasis Area and Severity Index [PASI] 75 responders), followed by ustekinumab (22 weeks), infliximab (19.5 weeks), adalimumab (18 weeks), etanercept (12.1 weeks in PASI 50 responders), and lastly efalizumab (9.6 weeks). Rebound was reported commonly for efalizumab (14%) and extremely rarely for etanercept (0.002%).


2010 ◽  
Vol 62 (4) ◽  
pp. 655-662 ◽  
Author(s):  
Misha Rosenbach ◽  
Sylvia Hsu ◽  
Neil J. Korman ◽  
Mark G. Lebwohl ◽  
Melodie Young ◽  
...  

2018 ◽  
Vol 154 (8) ◽  
pp. 934 ◽  
Author(s):  
Adam R. Ford ◽  
Michael Siegel ◽  
Jerry Bagel ◽  
Kelly M. Cordoro ◽  
Amit Garg ◽  
...  

2009 ◽  
Vol 60 (6) ◽  
pp. 962-971 ◽  
Author(s):  
C. Stanley Chan ◽  
Abby S. Van Voorhees ◽  
Mark G. Lebwohl ◽  
Neil J. Korman ◽  
Melodie Young ◽  
...  

2011 ◽  
Vol 7 (2) ◽  
pp. 113-123
Author(s):  
Xavier Juanola Roura ◽  
Pedro Zarco Montejo ◽  
Jesús Sanz Sanz ◽  
Santiago Muñoz Fernández ◽  
Juan Mulero Mendoza ◽  
...  

2008 ◽  
Vol 58 (1) ◽  
pp. 94-105 ◽  
Author(s):  
Mark Lebwohl ◽  
Jerry Bagel ◽  
Joel M. Gelfand ◽  
Dafna Gladman ◽  
Kenneth B. Gordon ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document